Beneficial role of central anticholinergic agent in preventing the development of symptoms in mouse model of post-traumatic stress disorder.

Objectives The present study was designed to investigate the effectiveness of trihexyphenidyl, a central anticholinergic drug, in preventing the post-traumatic stress disorder (PTSD) symptoms in a mouse model. Methods Mice were subjected to underwater trauma stress for 30 s on day 1 followed by three situational reminders (3rd, 7th and 14th day). Thereafter, the behavioral alterations including freezing behavior were noted on 21st day. The serum corticosterone levels were measured as a biochemical marker of trauma. Elevated plus maze test was done on day 1 and day 2 to assess the memory formation following exposure to trauma. Results Trauma and situational reminders were associated with a significant development of behavioral changes and freezing behavior on the 21st day. Moreover, there was also a significant decrease in the serum corticosterone levels. A single administration of trihexyphenidyl (2 and 5 mg/kg) significantly restored trauma associated-behavioral changes and serum corticosterone levels. Moreover, it significantly increased the transfer latency time on day 2 following stress exposure in comparison to normal mice suggesting the inhibition of memory formation during trauma exposure. Trihexyphenidyl also led to significant reduction in freezing behavior in response to situational reminders again suggesting the inhibition of formation of aversive fear memory. Conclusion The blockade of central muscarinic receptors may block the formation of aversive memory during the traumatic event, which may be manifested in form of decreased contextual fear response during situational reminders. Central anticholinergic agents may be potentially useful as prophylactic agents in preventing the development of PTSD symptoms.

Utility of specific IgG4 response in saliva and serum samples for the diagnosis and follow up of human neurocysticercosis.

This study was aimed to analyze the Ig subtypes and IgG1 and IgG4 subclass responses to crude soluble extract (CSE) antigen and Ag B of Cysticercus cellulosae in pre and post treatment (PT) saliva and serum samples for the diagnosis and follow-up of neurocysticercosis (NCC) patients. Saliva and serum samples collected from 55 patients (15 highly suggestive of NCC clinically and radiologically, 10 hydatidosis, 10 other helminthic infections, 10 tubercular meningitis, 10 neurological disorders other than NCC), 15 normal healthy subjects and 10 NCC patients at 1, 3 and 6 months following albendazole therapy were analyzed for specific IgG, IgG1, IgG4, IgM and IgA antibody responses by ELISA. With the use of CSE Ag, the rank orders in saliva for sensitivity was IgG (71.4%) > IgG1 (68.2%) > IgG4 (65.2%) > IgM (57.7%) > IgA (55.5%) and specificity IgG1 = IgA (93.2%) > IgG = IgG4 = IgM (91.6%) while in serum, sensitivity was IgG (78.9%) > IgG1 (71.4%) > IgG4 (68.2%) > IgA (65.2%) > IgM (62.5%) and specificity IgG1 = IgG4 (90.2%) > IgA (85.9%) > IgG (83.3%) > IgM (82.1%). With the use of Ag B in saliva, the sensitivity was IgG (65.2%) > IgG1 = IgG4 (62.5%) > IgM = IgA (55.5%) and specificity with the use of saliva was IgG1 = IgG4 = IgM (94.8%) > IgG (93.2%) > IgA (91.6%) while with serum the sensitivity was IgG = IgG1 (68.2%) > IgG4 (65.2%) > IgA (62.5%) > IgM (57.7%) and specificity was IgG1 (93.2%) > IgG4 = IgM (91.6%) > IgA (90.2%) > IgG (87.3%). Comparative analysis of antibody responses in patients with single Vs multiple CT scan lesions indicated higher sensitivity in multiple lesion patients. Antibody responses in PT samples indicated that the undetectable IgG4, IgM and IgA responses in saliva samples correlated well with the CT scan reports while in serum samples, responses persisted longer. In conclusion, this study indicated that due to the lower sensitivity of IgM and IgA responses in pretreatment samples, detection of IgG4 subclass in saliva to either CSE Ag or AgB may serve better marker in the NCC follow-up.